Earlier quoted context omitted.
The current n=94. The real n=43.5k data apparently will come later. Article doesn’t specify when, but “hopes” to have enough of the larger n analyzed to submit to regulators by 3rd week of November.
FWIW, N=94 seems ridiculously small to me. I realize there's ethical concerns in increasing exposure etc but in my experience, that's in the ballpark of sample sizes where unacknowledged heterogeneity can be manipulated to distort findings. I'm not suggesting Pfizer is up to something nefarious, just that the biomedical literature is littered with studies with N 40k in some ways is irrelevant if none of those partici…
What you're saying is the 9 is pretty close to 34 (60% effectiveness). No, it isn't. You'd need to quadruple the number of vaccinated cases to get there. Even if you double them, you're still at 80% so I'd take that as the realistic worst case.
Edit: Also, this is BioNTech's vaccine, not Pfizer's. They partnered with Pfizer as they have the facilities and scale for a massive rollout, but it was developed by BioNTech. I wish they were getting more credit in the US & UK coverage.